Leczenie środkami przeciwzakrzepowymi i odwrócenie ich działania

Reversal of antithrombotic agents. (opens new window)

Bauer KA.

Źródło‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Indeks‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (opens new window)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (opens new window)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Źródło‎: J Thromb Haemost 2015;13(10):1790-8.

Indeks‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (opens new window)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (opens new window)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Źródło‎: N Engl J Med 2019;380(14):1326-35.

Indeks‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (opens new window)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (opens new window)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Źródło‎: N Engl J Med 2016;375(12):1131-41.

Indeks‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (opens new window)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (opens new window)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Źródło‎: Circulation 2011;124(14):1573-9.

Indeks‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (opens new window)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (opens new window)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Źródło‎: Lancet 2015;385(9982):2077-87.

Indeks‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (opens new window)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (opens new window)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Źródło‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Indeks‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (opens new window)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (opens new window)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Źródło‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Indeks‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (opens new window)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (opens new window)

Levi M, Eerenberg E, Kamphuisen PW.

Źródło‎: J Thromb Haemost 2011;9(9):1705-12.

Indeks‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (opens new window)

Emergency reversal of warfarin anticoagulation. (opens new window)

Lin Y, Callum J.

Źródło‎: CMAJ 2010;182(18):2004.

Indeks‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (opens new window)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (opens new window)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Źródło‎: Thromb Haemost 2012;108(2):217-24.

Indeks‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (opens new window)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (opens new window)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Źródło‎: J Thromb Haemost 2008;6(4):622-31.

Indeks‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (opens new window)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (opens new window)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Źródło‎: Blood Adv 2019;3(2):158-67.

Indeks‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (opens new window)

Idarucizumab for dabigatran reversal. (opens new window)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Źródło‎: N Engl J Med 2015;373(6):511-20.

Indeks‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (opens new window)

Idarucizumab for dabigatran reversal - full cohort analysis. (opens new window)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Źródło‎: N Engl J Med 2017;377(5):431-41.

Indeks‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (opens new window)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (opens new window)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Źródło‎: Blood 2003;102(13):4594-9.

Indeks‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (opens new window)

Role of agents for reversing the effects of target-specific oral anticoagulants. (opens new window)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Źródło‎: Am J Health Syst Pharm 2017;74(2):54-61.

Indeks‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (opens new window)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (opens new window)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Źródło‎: Anesth Analg 2011;113(4):703-10.

Indeks‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (opens new window)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (opens new window)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Źródło‎: J Am Coll Cardiol 2017;70(24):3042-67.

Indeks‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (opens new window)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (opens new window)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Źródło‎: World Neurosurg 2014;81(1):110-5.

Indeks‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (opens new window)

Reversal of warfarin-induced hemorrhage in the emergency department. (opens new window)

Zareh M, Davis A, Henderson S.

Źródło‎: West J Emerg Med 2011;12(4):386-92.

Indeks‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (opens new window)

INTENSYWNA TERAPIA, STANY KRYTYCZNE

Leczenie środkami przeciwzakrzepowymi i odwrócenie ich działania

polski

Leczenie środkami przeciwzakrzepowymi i odwrócenie ich działania

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Leczenie środkami przeciwzakrzepowymi i odwrócenie ich działania

Reversal of antithrombotic agents. (opens new window)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (opens new window)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (opens new window)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (opens new window)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (opens new window)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (opens new window)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (opens new window)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (opens new window)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (opens new window)

Emergency reversal of warfarin anticoagulation. (opens new window)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (opens new window)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (opens new window)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (opens new window)

Idarucizumab for dabigatran reversal. (opens new window)

Idarucizumab for dabigatran reversal - full cohort analysis. (opens new window)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (opens new window)

Role of agents for reversing the effects of target-specific oral anticoagulants. (opens new window)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (opens new window)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (opens new window)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (opens new window)

Reversal of warfarin-induced hemorrhage in the emergency department. (opens new window)

Komitet Łączności ze Szpitalami (KŁS)

Informacje medyczne — pakiety

Materiały wideo

Leczenie środkami przeciwzakrzepowymi i odwrócenie ich działania

Wybierz swój język

Udostępnij